Empowered Funds LLC Acquires Shares of 28,726 Stryker Corporation $SYK

Empowered Funds LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 28,726 shares of the medical technology company’s stock, valued at approximately $9,044,000.

Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Norges Bank bought a new stake in shares of Stryker in the 4th quarter valued at about $1,822,272,000. Bank of America Corp DE acquired a new stake in shares of Stryker in the 2nd quarter worth $1,404,284,000. Auto Owners Insurance Co grew its stake in shares of Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares during the last quarter. Legal & General Group Plc acquired a new position in Stryker during the 2nd quarter valued at approximately $707,212,000. Finally, Jupiter Topco LLC acquired a new position in shares of Stryker in the 2nd quarter valued at $681,581,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $331.32 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The business’s 50 day moving average is $329.10 and its two-hundred day moving average is $331.47. The company has a market capitalization of $127.08 billion, a P/E ratio of 34.33, a P/E/G ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the company posted $3.13 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Activity

In related news, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 over the last 90 days. 4.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

SYK has been the subject of a number of recent research reports. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Royal Bank Of Canada cut their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. Raymond James Financial set a $370.00 price target on Stryker in a research report on Friday, July 31st. Finally, Leerink Partners dropped their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.